# Hemopatch Implication After Axillary Dissection for Breast Cancer

> **NCT06744998** · NA · NOT_YET_RECRUITING · sponsor: **European Institute of Oncology** · enrollment: 190 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DEVICE:** Hemopatch® (Baxter)

## Key facts

- **NCT ID:** NCT06744998
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06744998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06744998, "Hemopatch Implication After Axillary Dissection for Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06744998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*